Hricik D E, Mayes J T, Schulak J A
Transplantation Service, University Hospitals of Cleveland, OH 44106.
Transplantation. 1990 Aug;50(2):237-40. doi: 10.1097/00007890-199008000-00013.
To investigate the influence of therapy with cyclosporine on the generation of antibodies to OKT3, 51 renal transplant recipients previously maintained on CsA, azathioprine, and prednisone were allocated randomly either to receive 50% of their maintenance dose of CsA (group 1, n = 27) or to discontinue CsA (group 2, n = 24) during treatment with OKT3 for acute renal allograft rejection. In the month following therapy with OKT3, anti-OKT3 antibodies were detected in 11% of patients in group 1 and in 42% of patients in group 2 (P less than 0.02). No patient in group 1 developed antibody titers greater than 1:100, whereas 4 patients in group 2 developed titer greater than or equal to 1:1000. Rejection was reversed in 96% of patients in group 1 and in only 75% of patients in group 2 (P less than 0.03), suggesting that continued administration of reduced doses of CsA during therapy with OKT3 improves the short-term response to this monoclonal antibody. Results of this study suggest that concurrent administration of CsA during therapy with OKT3 inhibits the generation of anti-OKT3 antibodies and improves the response to this monoclonal antibody.
为研究环孢素治疗对OKT3抗体产生的影响，将51例先前接受环孢素（CsA）、硫唑嘌呤和泼尼松维持治疗的肾移植受者随机分为两组，在使用OKT3治疗急性肾移植排斥反应期间，一组接受50%维持剂量的CsA（第1组，n = 27），另一组停用CsA（第2组，n = 24）。在使用OKT3治疗后的一个月内，第1组11%的患者检测到抗OKT3抗体，第2组为42%（P < 0.02）。第1组无患者抗体滴度大于1:100，而第2组有4例患者抗体滴度大于或等于1:1000。第1组96%的患者排斥反应得到逆转，第2组仅为75%（P < 0.03），这表明在使用OKT3治疗期间持续给予低剂量的CsA可改善对这种单克隆抗体的短期反应。本研究结果提示，在使用OKT3治疗期间同时给予CsA可抑制抗OKT3抗体的产生，并改善对这种单克隆抗体的反应。
